TriSalus Life Sciences, Inc. Increase (Decrease) in Accrued Liabilities
TriSalus Life Sciences, Inc. (TLSI) reported Increase (Decrease) in Accrued Liabilities of $385.32 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-03-22
- TriSalus Life Sciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2021-12-31 was $361.05K.
- TriSalus Life Sciences, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $385.32K, a 59.63% decline from fiscal 2021.
- TriSalus Life Sciences, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $954.40K.
| Period end | Increase (Decrease) in Accrued Liabilities 1 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 4 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $385.32K 10-K · filed 2023-03-22 | ||||
| 2021-12-31 | $361.05K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-22 | $954.40K 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $593.35K 10-Q/A · filed 2021-12-13 | ||||
| 2020-12-31 | $103.22K 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | $1.00K 10-Q/A · filed 2021-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |